2015 Issue No. 2 - Week 3 (as of 20 January 2015) Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age) and adequate specimen collection rate, 2012–2014 3.0 2.5 Non-polio AFP rate
Polio Bulletin 100% 90% 80% 70% 60% Cases with adequate specimens
Chart 2. Percentage of cases with pending classification > 90 days after onset, 2014 CHN KHM LAO MYS PHL PNG VNM 0% 8.8% 20% 40% 60% 80% 100% 7.3% 1.4% 3.8% 6.3% 2.4% 90.9%
2.0 1.5 1.0 0.5 0.0 12 13 14 CHN 12 13 14 KHM 12 13 14 LAO 12 13 14 MYS 12 13 14 PHL 12 13 14 PNG 12 13 14 VNM
50% 40% 30% 20% 10% 0%
Chart 3. Polio immunization status of reported AFP cases, 2014 100%
Chart 4. Percentage of samples received at the lab ≤ 3 days of collection, 2014 100%
80%
80%
60%
60%
53%
55%
40%
40% 25% 20%
38%
20%
0% CHN KHM LAO MYS 1-2 doses
PHL 0 doses
PNG Unknown
VNM
0% CHN
0% KHM
0% LAO MYS PHL
0% PNG VNM
≥ 3 doses
CONTACT US
Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).
Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization
Table 1. Classification of AFP cases with onset in 2014 and key surveillance indicators 2013 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with % with % with any investigated adequate 60-day 3 2 days of ≤ specimen 5 specimens 2 4 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date Days since last report 6
2014 Indicators
Poliocompatible
Discarded (Non-polio)
Total
> 90 days 1 # (%)
≥1
Australia Brunei Darussalam Cambodia China Hong Kong (China) Japan Lao People's Democratic Republic Macao (China) Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries Total 1. 2. 3. 4. 5. 6.
62 1 73 5623 12 0 48 1 155 7 12 18 277 84 7 459 8 6847
44 1 46 2225 8 167 25 1 77 8 9 30 378 72 6 231 10 3338
50 2 72 5555 19 0 26 1 159 8 5 11 251 88 8 330 11 6596
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
47 2 60 4389 18 23 1 132 4 4 0 211 87 8 244 7 5237
3 0 12 1166 1 3 0 27 4 1 11 40 1 0 86 4 1359
1 (2.0%) 0 (0.0%) 1 (1.4%) 408 (7.3%) 0 (0.0%) 1 (3.8%) 0 (0.0%) 10 (6.3%) 0 (0.0%) 1 (20.0%) 10 (90.9%) 6 (2.4%) 0 (0.0%) 0 (0.0%) 29 (8.8%) 2 (18.2%) 469 (7.1%) Green Yellow Red
1.14 2.00 1.57 2.50 2.38 1.04 1.00 2.06 1.00 0.56 0.37 0.66 1.22 1.33 1.43 1.10 1.98
48% 50% 96% 92% 89% 54% 0% 74% 88% 40% 36% 60% 86% 75% 96% 64% 90%
80% 50% 100% 99% 100% 85% 100% 97% 100% 80% 91% 92% 100% 100% 98% 100% 98%
86% 100% 93% 100% 100% 92% 100% 68% 100% 100% 73% 97% 98% 88% 93% 91% 98%
0% 100% 67% 89% 100% 100% 100% 69% 100% 67% 0% 6% 100% 100% 92% 75% 71%
03-Dec-14 30-Sep-14 03-Jan-15 15-Jan-15 08-Jan-15 04-Nov-14 13-Jan-15 26-Dec-14 08-Jan-15 29-Oct-14 03-Dec-14 09-Dec-14 16-Jan-15 07-Jan-15 16-Dec-14 08-Dec-14
48 112 17 5 12 77 7 25 12 83 48 42 4 13 35 43
Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases with at least one specimen Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens for which the 60-day follow-up evaluation has been completed Countries are expected to submit data at least once per month to WPRO
Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target
2
Polio Bulletin
Table 2. Laboratory investigation of AFP cases with onset in 2014 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with positive specimens L20B positive + NPEV NPEV only Pending ≤ 14 Negative days Intratypic % % results differentiation Latest Pending reported specimens / Sequencing positive report date > 14 2 ≤ 14 days for NPEV lab 1 days ≥ 80% No. of isolates referred Type 1 W ild Sabin VDPV W ild Type 2 Sabin Intratypic differentiation (ITD) results Type 3 VDPV Wild Sabin VDPV NPEV 3
1
Pending ITD
% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%
Australia Brunei Darussalam Papua New Guinea Pacific island countries Japan Cambodia Lao People's Democratic Republic Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Macao (China) Total
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR PHI IESR RITM NIH SGH NIHE PI CCDC Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC
45 2 10 12 0 72 24 156 8 5 326 88 8 213 136 5489 314 37 200 127 334 266 314 144 506 256 314 183 55 100 373 27 223 401 26 98 253 180 72 200 40 176 128 86 35 19 2 19 0 6613
0 0 0 0 5 1 0 0 0 4 0 0 0 0 109 20 1 2 0 4 6 10 2 4 4 21 2 1 1 5 2 3 4 0 1 11 2 0 0 0 1 0 1 1 0 0 0 119
0 0 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3
2 0 4 0 11 5 4 1 1 12 8 0 29 16 570 26 0 25 10 47 52 37 7 59 36 3 27 7 4 38 0 2 39 3 5 37 20 14 25 7 23 11 3 0 3 0 4 667
41 2 5 11 56 18 147 5 4 305 78 8 179 120 4753 264 34 173 117 282 206 262 135 440 210 286 153 43 94 329 25 213 351 23 89 204 158 58 174 33 152 115 78 34 16 2 15 5747
2 0 0 1 0 0 5 1 0 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15
0 0 0 0 0 0 0 1 0 0 0 0 5 0 56 4 2 0 0 1 2 4 0 3 6 4 1 4 1 1 0 5 7 0 3 1 0 0 1 0 0 2 4 0 0 0 0 62
96% 50% 100% 100% 96% 100% 100% 100% 91% 89% 97% 100% 99% 93% 74% 82% 83% 92% 79% 80% 63% 69% 89% 81% 89% 79% 92% 64% 87% 83% 98% 53% 38% 92% 96% 51% 68% 72% 89% 75% 58% 85% 63% 79% 92% 67% 93% 75%
2% 0% 50% 0% 13% 19% 2% 15% 18% 3% 10% 0% 12% 11% 9% 8% 0% 9% 7% 11% 16% 8% 4% 10% 13% 1% 13% 12% 4% 8% 0% 1% 9% 10% 4% 12% 8% 15% 11% 15% 13% 8% 2% 0% 16% 0% 11% 9%
02-Jan-15 02-Jan-15 02-Jan-15 02-Jan-15 19-Jan-15 24-Dec-14 10-Dec-14 08-Jan-15 12-Jan-15 09-Jan-15 16-Jan-15 14-Jan-15 09-Jan-15 13-Jan-15 15-Jan-15
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR NIID IESR RITM NIH SGH NIHE PI Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC
0 0 4 0 0 10 0 0 0 0 9 2 0 0 0 273 39 8 3 6 9 12 9 6 6 4 44 4 0 2 8 6 10 10 10 4 24 8 4 11 0 2 10 8 6 0 0 0 0 298
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 2 0 57 6 2 0 2 4 0 2 0 1 2 7 1 0 3 0 2 4 2 2 7 0 0 0 2 4 4 0 59
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 10 6 0 96 12 0 0 2 3 7 4 2 2 2 15 0 2 3 2 4 4 4 2 7 2 2 7 0 2 2 4 112
0 0 0 0 4 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 0 0 0 104 21 6 3 2 2 5 1 3 3 0 17 1 0 2 4 2 2 4 0 10 4 2 4 0 2 2 2 106
0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2
2 0 0 2 7 0 0 0 0 0 0 0 1 0 0 0 2 0 0 0 0 0 0 0 0 2 0 0 0 2 0 0 11
0 0 1 0 3 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100% 100% 100% 100% 95% 90% 100% 100% 100% 78% 100% 100% 100% 75% 100% 97% 100% 100% 100% 100% 88% 100% 100% 100% 93% 100% 100% 88% 100% 100% 100% 100% 95%
13-Jan-15 13-Jan-15
PHLC PHLC
1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform ITD from 2013
3
Polio Bulletin
Table 3. Laboratory confirmation of polio isolates from other sources in 2014 Non-AFP cases Country Intratypic Total number Total number differentiation of non-AFP of non-AFP lab 2 cases tested cases with polio isolates for polio Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin NPEV Discordant Total number Pending of samples grown pending ITD processed sequencing VDPV in L20B Total number of samples with polio isolates Type 1 Wild Sabin VDPV
1
Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 Sabin NPEV Discordant Pending grown pending ITD sequencing VDPV in L20B
Australia Japan Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Total
VIDRL NIID IMR NIID IESR RITM NIH SGH NIHE PI Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC PHLC
65 0 0 140 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 207
0 0 0 1 1 1
0 0 0 0 0 0
0 0 0 1 1 1
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 17 0 0 0 17
0 0 0 0 0 0
0 0 0 0 0 0
3 0 21 0 0 0 0 0 0 0 167 0 0 14 0 48 0 0 18 0 0 0 0 0 0 48 12 0 0 0 27 0 0 0 0 0 0 0 0 0 0 0 0 191
0 7 167 14 48 18 48 12 27 174
0 0 0 0 0 0 0 0 0
1 79 1 21 11 13 6 27 80
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
1 129 4 22 37 16 12 38 130
0 2 0 0 1 0 0 1 2
0 0 0 0 0 0 0 0 0
5 115 0 15 47 23 10 20 120
0 0 0 0 0 0 0 0 0
7 0 0 0 0 0 0 0 7
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)
4
Polio Bulletin
Table 4. Vaccine-derived poliovirus, 2000–2014 Country Cambodia iVDPV1 (1 case) aVDPV1 (1 case) aVDPV3 (1 case) aVDPV3 (1 case)
2000
2001
2002
2003
2004
2005 cVDPV3 (1 case)
2006 cVDPV3 (1 case)
2007
2008
2009
2010
2011
2012
2013
2014
China
aVDPV1 (1 case)
cVDPV1 (2 cases) aVDPV1 (1 case) aVDPV1 (3 cases) ?VDPV1 (4 cases) iVDPV2 (1 case) ?VDPV1 (7 cases) ?VDPV1 (1 case) ?VDPV2 (1 case) VDPV3 (1 case) ?VDPV? (3 cases) ?VDPV? (1 case) aVDPV2 (1 case) ?VDPV? (2 cases) ?VDPV? (1 case) ?VDPV3 (1 case)
aVDPV2 (1 case)
aVDPV1 (1 case) aVDPV1 (1 case) aVDPV2 (3 cases) aVDPV2 (5 cases) aVDPV2 (2 cases) aVDPV2 (1 case) aVDPV2 (2 cases) cVDPV2 (2 cases) aVDPV3 (2 cases) cVDPV2 (3 cases) iVDPV2 + iVDPV3 (1 case) ?VDPV3 (1 case) iVDPV2 (2 cases) iVDPV2 + iVDPV3 (1 case) iVDPV3 (1 case)
Hong Kong (China) Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam cVDPV1 (3 cases)
aVDPV2 (2 cases)
5
Polio Bulletin